PEDIATRICS Vol. 115 No. 4 April 2005, pp. 1018-1029 (doi:10.1542/peds.2004-2183)
A Multicenter, Randomized, Masked, Comparison Trial of Lucinactant, Colfosceril Palmitate, and Beractant for the Prevention of Respiratory Distress Syndrome Among Very Preterm Infants
* Department of Pediatrics, University of Texas Health Science Center at Houston, Houston, Texas
University of Medical Sciences, Poznan, Poland, and Polish Mother's Memorial Hospital Research Institute, Lodz, Poland
Jackson Memorial Hospital, University of Miami, Miami, Florida
|| National Institute of Perinatology, Mexico City, Mexico
¶ Hospital São Paulo, University of Sao Paulo, Paulista School of Medicine, Sao Paulo, Brazil
# Regional Clinical Hospital Guillermo Grant-Benavente, University of Concepción, Concepción, Chile
** Neonatology Clinic, Warsaw Medical University, Warsaw, Poland
St Charles Medical Center, Bend, Oregon
Discovery Laboratories, Doylestown, Pennsylvania
|||| Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts
¶¶ Statistics and Consulting Unit, Department of Mathematics and Statistics, Boston University, Boston, Massachusetts
Background and Objective. Evidence suggests that synthetic surfactants consisting solely of phospholipids can be improved through the addition of peptides, such as sinapultide, that mimic the action of human surfactant protein-B (SP-B). A synthetic surfactant containing a mimic of SP-B may also reduce the potential risks associated with the use of animal-derived products. Our objective was to compare the efficacy and safety of a novel synthetic surfactant containing a functional SP-B mimic (lucinactant; Discovery Laboratories, Doylestown, PA) with those of a non–protein-containing synthetic surfactant (colfosceril palmitate; GlaxoSmithKline, Brentford, United Kingdom) and a bovine-derived surfactant (beractant; Abbott Laboratories, Abbott Park, IL) in the prevention of neonatal respiratory distress syndrome (RDS) and RDS-related death.
Methods. We assigned randomly (double-masked) 1294 very preterm infants, weighing 600 to 1250 g and of 
32 weeks gestational age, to receive colfosceril palmitate (n = 509), lucinactant (n = 527), or beractant (n = 258) within 20 to 30 minutes after birth. Primary outcome measures were the rates of RDS at 24 hours and the rates of death related to RDS during the first 14 days after birth. All-cause mortality rates, bronchopulmonary dysplasia (BPD) rates, and rates of other complications of prematurity were prespecified secondary outcomes. Primary outcomes, air leaks, and causes of death were assigned by an independent, masked, adjudication committee with prespecified definitions. The study was monitored by an independent data safety monitoring board.
Results. Lucinactant reduced significantly the incidence of RDS at 24 hours, compared with colfosceril (39.1% vs 47.2%; odds ratio [OR]: 0.68; 95% confidence interval [CI]: 0.52–0.89). There was no significant difference in comparison with beractant (33.3%). However, lucinactant reduced significantly RDS-related mortality rates by 14 days of life, compared with both colfosceril (4.7% vs 9.4%; OR: 0.43; 95% CI: 0.25–0.73) and beractant (10.5%; OR: 0.35; 95% CI: 0.18–0.66). In addition, BPD at 36 weeks postmenstrual age was significantly less common with lucinactant than with colfosceril (40.2% vs 45.0%; OR: 0.75; 95% CI: 0.56–0.99), and the all-cause mortality rate at 36 weeks postmenstrual age was lower with lucinactant than with beractant (21% vs 26%; OR: 0.67; 95% CI: 0.45–1.00).
Conclusions. Lucinactant is a more effective surfactant preparation than colfosceril palmitate for the prevention of RDS. In addition, lucinactant reduces the incidence of BPD, compared with colfosceril palmitate, and decreases RDS-related mortality rates, compared with beractant. Therefore, we conclude that lucinactant, the first of a new class of surfactants containing a functional protein analog of SP-B, is an effective therapeutic option for preterm infants at risk for RDS.
Key Words: lucinactant • colfosceril palmitate • beractant • surfactant • respiratory distress syndrome
Abbreviations: RDS, respiratory distress syndrome • BPD, bronchopulmonary dysplasia • OR, odds ratio • CI, confidence interval • IVH, intraventricular hemorrhage • PVL, periventricular leukomalacia • PMA, postmenstrual age • SP, surfactant protein • DPPC, dipalmitoylphosphatidylcholine • FIO2, fraction of inspired oxygen
Accepted Dec 6, 2004.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  W. Lenney, A. L. Boner, L. Bont, A. Bush, K-H. Carlsen, E. Eber, B. Fauroux, M. Gotz, A. Greenough, J. Grigg, et al. Medicines used in respiratory diseases only seen in children Eur. Respir. J., September 1, 2009; 34(3): 531 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D G Sweet and H L Halliday The use of surfactants in 2009 Arch. Dis. Child. Ed. Pract., June 1, 2009; 94(3): 78 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bhandari and V. Bhandari Pitfalls, Problems, and Progress in Bronchopulmonary Dysplasia Pediatrics, June 1, 2009; 123(6): 1562 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Laughon, C. Bose, F. Moya, J. Aschner, S. M. Donn, C. Morabito, J. J. Cummings, R. Segal, C. Guardia, G. Liu, et al. A Pilot Randomized, Controlled Trial of Later Treatment With a Peptide-Containing, Synthetic Surfactant for the Prevention of Bronchopulmonary Dysplasia Pediatrics, January 1, 2009; 123(1): 89 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. E. Truog 21st-Century Use for Surfactant? Pediatrics, January 1, 2009; 123(1): 173 - 174. [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Lal and S. K. Sinha Review: Surfactant respiratory therapy using Surfaxin/sinapultide Therapeutic Advances in Respiratory Disease, October 1, 2008; 2(5): 339 - 344. [Abstract] [PDF]
|
|
|
|
|
|
F. Moya, S. Sinha, and R. B. D'Agostino Sr Surfactant-Replacement Therapy for Respiratory Distress Syndrome in the Preterm and Term Neonate: Congratulations and Corrections Pediatrics, June 1, 2008; 121(6): 1290 - 1291. [Full Text] [PDF]
|
|
|
|
|
|
W. A. Engle and A. R. Stark Surfactant-Replacement Therapy for Respiratory Distress Syndrome in the Preterm and Term Neonate: Congratulations and Corrections: In Reply Pediatrics, June 1, 2008; 121(6): 1291 - 1292. [Full Text] [PDF]
|
|
|
|
|
|
W. A. Engle and and the Committee on Fetus and Newborn Surfactant-Replacement Therapy for Respiratory Distress in the Preterm and Term Neonate Pediatrics, February 1, 2008; 121(2): 419 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. T. Lavin Meta-Analysis Combining 2 Previously Reported Trials on Respiratory Distress Syndrome in Neonates Pediatrics, November 1, 2007; 120(5): 1223 - 1224. [Full Text] [PDF]
|
|
|
|
|
|
S. Senn, M. Costantini, and G. Rizzi Meta-Analysis Combining 2 Previously Reported Trials on Respiratory Distress Syndrome in Neonates Pediatrics, November 1, 2007; 120(5): 1224 - 1225. [Full Text] [PDF]
|
|
|
|
|
|
F. Moya, S. Sinha, and R. B. D'Agostino Sr Meta-Analysis Combining 2 Previously Reported Trials on Respiratory Distress Syndrome in Neonates: In Reply Pediatrics, November 1, 2007; 120(5): 1225 - 1226. [Full Text] [PDF]
|
|
|
|
|
|
F. Moya, S. Sinha, J. Gadzinowski, R. D'Agostino, R. Segal, C. Guardia, J. Mazela, G. Liu, and on behalf of the SELECT and STAR Study Investigato One-Year Follow-up of Very Preterm Infants Who Received Lucinactant for Prevention of Respiratory Distress Syndrome: Results From 2 Multicenter Randomized, Controlled Trials Pediatrics, June 1, 2007; 119(6): e1361 - e1370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Gastiasoro-Cuesta, F. J. Alvarez-Diaz, C. Rey-Santano, A. Arnaiz-Renedo, B. Loureiro-Gonzalez, and A. Valls-i-Soler Acute and Sustained Effects of Lucinactant Versus Poractant-{alpha} on Pulmonary Gas Exchange and Mechanics in Premature Lambs With Respiratory Distress Syndrome Pediatrics, February 1, 2006; 117(2): 295 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. R. Moya, S. K. Sinha, and R. D'Agostino Surfactant Trials Pediatrics, January 1, 2006; 117(1): 245 - 247. [Full Text] [PDF]
|
|
|
|
|
|
J. Kattwinkel Synthetic Surfactants: The Search Goes on Pediatrics, April 1, 2005; 115(4): 1075 - 1076. [Full Text] [PDF]
|
|
